diastolic hypertension with obesity
Conditions
Interventions
Experimental group:the basis of standard treatment of hypertension with smegelutide
control group:the basis of standard treatment of hypertension
Sponsors
The First Affiliated Hospital, Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Male or female = 18 years old and = 75, and BMI = 28 kg/m2; 2. Diagnosis of essential hypertension DBP = 90mmHg and 90cm or female > 85cm.
Exclusion criteria
Exclusion criteria: 1. GLP-1 or SGLT-2 has been used in the past 3 months; 2. Diagnosed diabetes patients, HbA1 = 6.5; 3. History of thyroid cancer or pancreatitis; 4. Take more than 4 kinds of antihypertensive drugs; 5. Sitting diastolic pressure DBP = 110 mmHg or sitting systolic pressure SBP = 180 during screening; 6. Known intractable, secondary or malignant hypertension; 7. Severe liver or kidney disease (ALT>3 times the upper limit of normal value, or end-stage renal dialysis or eGFR2.5 mg/dl [>221 µ mol/L ]) 8. Occurrence of acute coronary syndrome (non ST wave elevated myocardial infarction (STEMI), STEMI and unstable angina pectoris), stroke or transient ischemic attack; 9. History of second or third degree heart block or sick sinus syndrome, unless a pacemaker is installed; 10. NYHA Grade III-IV heart failure; In the last 6 months, the patient was hospitalized due to the deterioration of chronic heart failure; 11. Severe valve disease; The possibility of surgery or percutaneous valve replacement during the study period; 12. Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Rheumatic heart disease; Congenital heart disease; 13. Other serious diseases that affect the entry or survival of participants, such as malignant tumors or acquired immunodeficiency syndrome; 14. Cognitive disorders or serious neuropsychiatric diseases that cannot provide their informed consent; 15. Participants preparing for pregnancy and/or lactation; 16. People with special eating habits, such as vegetarians; 17. Weight loss surgery and other gastrointestinal surgery causing chronic malabsorption in the past two years; 18. Other circumstances deemed unsuitable by the investigators; 19. Participants who are participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| diastolic blood pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Systolic pressure;Body Mass Index;Waist-to-Hip Ratio;low-density lipoprotein;high-density lipoprotein;triacylglycerol;Cholesterol;Uric acid;Estimated Glomerular Filtration Rate; | — |
Countries
Chine
Contacts
Public ContactChen Ailan
The First Affiliated Hospital, Guangzhou Medical University
Outcome results
None listed